会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Indoline-sulfonamides compounds
    • 二氢吲哚磺酰胺化合物
    • US07741495B2
    • 2010-06-22
    • US11798079
    • 2007-05-10
    • Jing-Ping LiouJang-Yang ChangHsing-Pang Hsieh
    • Jing-Ping LiouJang-Yang ChangHsing-Pang Hsieh
    • C07D209/44A61K31/41
    • C07D401/12C07D209/08C07D405/12C07D409/12
    • A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R″—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R′ and R″ independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.
    • 公开了一系列二氢吲哚磺酰胺化合物。 二氢吲哚磺酰胺化合物的配方如式(I)所示。 在式(I)中,R 1为H或卤素; R2是Ar,Ar-C(O) - ,Ar-CH2-,Ar-SO2-,Ar-O-C(O)或R“-C(O) - ,Ar是取代或未取代的C5- C20芳基,环基,杂环基或杂芳基,R'和R“独立地为C 1 -C 10烷基或C 1 -C 10烷氧基; 且R 3为C 5 -C 15芳基或C 1 -C 10烷基。 本发明中公开的二氢吲哚磺酰胺化合物的特征在于抑制微管蛋白聚合,并用合适的药学上可接受的载体处理癌症和其它微管蛋白聚合相关疾病。